Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

This was a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection. A single arm, non-randomized, open-label phase was added to the protocol after completion of enrollment in the randomized phase of the study. The study had three phases: Screening Period, Treatment Period, and Follow-Up Period.